Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Wagner-Drouet, Eva-Maria  [Clear All Filters]
2019
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.
2022
Kreft A, Alverson C, Wagner-Drouet E-M, Ries I, Sommer C, Nat MSchindelde. Veno-occlusive disease of the lung after allogeneic haematopoietic stem-cell transplantation: An autopsy study. Pathol Res Pract. 2022;231:153799.
2023
Kriege O, Kreft A, Hauptrock B, Wölfinger P, Theobald M, Wagner-Drouet E-M. Diagnosis of sinusoidal obstruction syndrome: can biopsy be the key?. Ann Hematol. 2023.
2024
Beelen DWilhelm, Iacobelli S, Koster L, Eikema D-J, van Biezen A, Stölzel F, Ciceri F, Bethge W, Dreger P, Wagner-Drouet E-M, et al. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. Bone Marrow Transplant. 2024.
Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.